Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Gilead Sciences Inc GILD

Healthcare Biotechnology

Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, coronavirus disease 2019 (COVID-19) and cancer. It is focused on the discovery, development and commercialization of medicines in areas of unmet medical need. Its portfolio of marketed products... see more

Add To Watchlist

Recent & Breaking News (NDAQ:GILD)

Gilead Announces New Data on Biktarvy® for the Treatment of HIV in Black Americans

Business Wire October 21, 2020

Gilead Presents New Data from Antiviral Development Programs at IDWeek 2020

Business Wire October 19, 2020

European CHMP Adopts Positive Opinion for Kite's KTE-X19 for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Business Wire October 16, 2020

Gilead Sciences to Release Third Quarter 2020 Financial Results on Wednesday, October 28, 2020

Business Wire October 14, 2020

Gilead Sciences Announces Expiration of Hart-Scott-Rodino Waiting Period for Immunomedics Tender Offer

Business Wire October 14, 2020

Phase 2b/3 Trial Shows Efficacy of Filgotinib for the Induction and Maintenance of Remission in Moderately and Severely Active Ulcerative Colitis

Business Wire October 12, 2020

Dow Heads for Best Week Since August

Livemoney October 9, 2020

Final Results of National Institute of Allergy and Infectious Diseases' ACTT-1 Trial Published in New England Journal of Medicine Expand Clinical Benefits of Veklury® (remdesivir) for the Treatment of COVID-19

Business Wire October 8, 2020

Gilead Sciences Signs Joint Procurement Agreement With the European Commission for Veklury® (remdesivir)

Business Wire October 8, 2020

Gilead Presents Biktarvy® Findings From Switch Studies & Analysis of Real-World BICSTaR Study At HIV Glasgow 2020

Business Wire October 5, 2020

Gilead Sciences Update on Supply and Distribution of Veklury® (remdesivir) in the United States

Business Wire October 1, 2020

Gilead Sciences Presents Data From HIV Research and Development Programs at HIV Glasgow 2020

Business Wire September 30, 2020

European Commission Grants Marketing Authorization for Jyseleca® ? (Filgotinib) for the Treatment of Adults With Moderate to Severe Active Rheumatoid Arthritis

Business Wire September 25, 2020

Jyseleca® (Filgotinib) Approved in Japan for Rheumatoid Arthritis

Business Wire September 25, 2020

Gilead Sciences Prices $7.25 Billion of Senior Unsecured Notes

Business Wire September 23, 2020

Gilead's Magrolimab, an Investigational Anti-CD47 Monoclonal Antibody, Receives FDA Breakthrough Therapy Designation for Treatment of Myelodysplastic Syndrome

Business Wire September 15, 2020

SHAREHOLDER ALERT: WeissLaw LLP Investigates Immunomedics, Inc.

PR Newswire September 14, 2020

SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Immunomedics, Inc. Buyout

GlobeNewswire September 14, 2020

Vaccine Tests Back on Again, Stocks Hike

Livemoney September 14, 2020

Gilead Sciences to Acquire Immunomedics

Business Wire September 13, 2020